Department of Surgery and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
J Pathol Clin Res. 2021 Nov;7(6):556-564. doi: 10.1002/cjp2.231. Epub 2021 Jun 22.
Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer and its incidence is increasing. Preoperative diagnosis is warranted in order to avoid 'two-stage' procedures that are associated with additional costs and higher radioactive iodine remnant uptake. In the setting of thyroid cancer, somatic BRAF V600E-mutations are highly specific for PTC and can be analyzed in aspirates from fine-needle aspiration cytology (FNAC). The 'gold standard' to perform FNAC is ultrasound guidance. Here, we analyze whether adding BRAF V600E-mutation analysis could be of value in palpation-guided FNACs. A total of 430 consecutive patients were included. Ultrasound-guided FNACs were performed in 251 patients and 179 patients underwent palpation-guided FNACs. BRAF V600E-mutation analysis was performed using two methods, an allele-specific polymerase chain reaction (PCR) analyzed by capillary gel electrophoresis (PCR/Qiaxcel), and a droplet digital PCR (ddPCR) assay. A total of 80 patients underwent surgery, and histology revealed 25 patients to have PTC. Of the 25 PTCs, 23 (92%) showed a BRAF V600E-mutation. Both mutation analysis methods (PCR/Qiaxcel and ddPCR) produced concordant results. In the ultrasound-guided group, the preoperative diagnostic sensitivity of FNAC using the Bethesda classification alone was very high and additional BRAF V600E-mutation analysis added little to the preoperative diagnostic sensitivity. By contrast, in the palpation-guided group, by adding BRAF V600E-mutation analysis, eight instead of four patients were diagnosed of having PTC. This increase in the diagnostic sensitivity was statistically significant (p < 0.05). The costs per sample were as low as 62 USD (PCR/Qiaxcel and ddPCR) and 35 USD (PCR/Qiaxcel only). Ultrasound-guided FNAC should be aimed for when dealing with thyroid nodules. However, if palpation-guided FNAC cannot be avoided or may be required due to resource utilization, adding BRAF V600E-mutation analysis using the methods described in this study might significantly increase the proportion of preoperatively diagnosed PTCs. The additional costs can be considered very reasonable.
甲状腺乳头状癌(PTC)是最常见的甲状腺癌类型,其发病率正在增加。为了避免与更高放射性碘残留摄取相关的“两阶段”手术,术前诊断是必要的。在甲状腺癌的背景下,体细胞 BRAF V600E 突变对 PTC 具有高度特异性,并且可以在细针抽吸细胞学(FNAC)的抽吸物中进行分析。进行 FNAC 的“金标准”是超声引导。在这里,我们分析在触诊引导的 FNAC 中添加 BRAF V600E 突变分析是否有价值。共纳入 430 例连续患者。在 251 例患者中进行了超声引导 FNAC,在 179 例患者中进行了触诊引导 FNAC。使用两种方法进行 BRAF V600E 突变分析,一种是通过毛细管凝胶电泳(PCR/Qiaxcel)分析的等位基因特异性聚合酶链反应(PCR),另一种是液滴数字 PCR(ddPCR)检测。共有 80 例患者接受了手术,组织学显示 25 例患者患有 PTC。在 25 例 PTC 中,23 例(92%)显示 BRAF V600E 突变。两种突变分析方法(PCR/Qiaxcel 和 ddPCR)均产生一致的结果。在超声引导组中,仅使用 Bethesda 分类的 FNAC 的术前诊断敏感性非常高,并且额外的 BRAF V600E 突变分析对术前诊断敏感性几乎没有增加。相比之下,在触诊引导组中,通过添加 BRAF V600E 突变分析,将 8 例而非 4 例患者诊断为 PTC。这种诊断敏感性的增加具有统计学意义(p<0.05)。每个样本的成本低至 62 美元(PCR/Qiaxcel 和 ddPCR)和 35 美元(仅 PCR/Qiaxcel)。在处理甲状腺结节时,应针对超声引导 FNAC。然而,如果由于资源利用而无法避免触诊引导 FNAC 或可能需要触诊引导 FNAC,则使用本研究中描述的方法添加 BRAF V600E 突变分析可能会显著增加术前诊断为 PTC 的比例。额外的成本可以被认为是非常合理的。